01—Abstract
Summary
Summary of the 8-K filed January 13, 2025. Cited figures are marked; the original filing is the authoritative source.
DexCom (DXCM) furnished an 8-K on January 13, 2025, in connection with CEO Kevin Sayer's presentation at the J.P.
Morgan Healthcare Conference, announcing preliminary, unaudited results for Q4 and full-year 2024 along with initial 2025 guidance. Q4 2024 total revenue is at least $1.113 billiona, up 8% year over year, with U.S. revenue of roughly $803 million (+4%) and International revenue of roughly $310 million (+17%). Full-year 2024 preliminary revenue is approximately $4.032 billion, up 11% from 2023.
Profitability guidance for 2024 was lowered. Non-GAAP gross profit margin is now expected at 62%b and non-GAAP operating margin at 19%. Management attributed the Q4 gross margin pressure to a non-cash charge tied to inventory damaged in transit and build configurations that reduced production yield.
Investors should weigh the top-line strength against this margin shortfall, which is the most notable negative in the release. For 2025, DexCom guided to total revenue of $4.60 billionc, about 14% growth, citing rising CGM access and awareness, the continued rollout of Stelo, international expansion, and market dynamics. It also expects non-GAAP gross margin of roughly 64-65% and non-GAAP operating margin of about 21%, implying margin recovery.
These figures are preliminary and subject to finalization in the 10-K, with full audited results due February 13, 2025. The company did not provide reconciliations of its non-GAAP guidance to GAAP measures, citing unpredictable items.
02—Key points
Key Highlights
- Q4 2024 preliminary revenue of at least $1.113 billion, up 8% YoY: U.S. about $803M (+4%), International about $310M (+17%)
- FY2024 preliminary revenue of approximately $4.032 billion, up 11% from 2023
- 2024 non-GAAP gross margin guidance updated to 62% and non-GAAP operating margin to 19%
- Q4 gross margin hit by a non-cash charge for inventory damaged in transit and build configurations that lowered production yield
- 2025 revenue outlook of $4.60 billion, about 14% growth, driven by CGM access, Stelo rollout, and international expansion
- 2025 non-GAAP gross margin guided to roughly 64-65% and non-GAAP operating margin to about 21%
- Audited Q4 and FY2024 results scheduled for February 13, 2025, with a conference call at 4:30 p.m. ET
03—Questions
Frequently Asked Questions
Why did DexCom lower its 2024 margin guidance?
The Q4 2024 gross margin was adversely affected by a non-cash charge, primarily for inventory damaged in transit and for certain build configurations that reduced production yield. This pushed the 2024 non-GAAP gross margin to about 62% and operating margin to about 19%.
Is DexCom's revenue growth still healthy despite the margin issues?
Yes. Full-year 2024 revenue grew about 11% to roughly $4.032 billion, and International revenue grew 17% in Q4, outpacing U.S. growth of 4%. Management also guides to about 14% revenue growth in 2025.
What drives the expected 2025 margin improvement?
The company guides to non-GAAP gross margin of about 64-65% and non-GAAP operating margin of about 21% for 2025. The release does not detail the specific drivers, so the figures should be verified against the forthcoming 10-K and earnings call.
Are these preliminary numbers final?
No. The Q4 and full-year 2024 results are preliminary and unaudited and remain subject to finalization in the Form 10-K. Audited results are scheduled for release on February 13, 2025, after market close.
Why are the non-GAAP guidance figures not reconciled to GAAP?
DexCom states that certain items affecting these measures are uncertain or outside its control and cannot be reasonably predicted, so a reconciliation is not available without unreasonable effort.
04—Continue